ePHex: a phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria.
Oxabact
Oxalate
Oxalobacter formigenes
Primary hyperoxaluria
eGFR
Journal
Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
14
12
2021
accepted:
14
04
2022
revised:
23
03
2022
pubmed:
14
5
2022
medline:
22
12
2022
entrez:
13
5
2022
Statut:
ppublish
Résumé
Primary hyperoxalurias (PHs) are rare genetic diseases that increase the endogenous level of oxalate, a waste metabolite excreted predominantly by the kidneys and also the gut. Treatments aim to improve oxalate excretion, or reduce oxalate generation, to prevent kidney function deterioration. Oxalobacter formigenes is an oxalate metabolizing bacterium. This Phase III, double-blind, placebo-controlled randomized trial investigated the effectiveness of orally administered Oxabact™, a lyophilized O. formigenes formulation, at reducing plasma oxalate levels in patients suffering from PH. Subjects (≥ 2 years of age) with a diagnosis of PH and maintained but suboptimal kidney function (mean estimated glomerular filtration rate at baseline < 90 mL/min/1.73 m Forty-three subjects were screened, 25 were recruited and one was discontinued. At Week 52, O. formigenes was established in the gut of subjects receiving Oxabact. Despite decreasing plasma oxalate level in subjects treated with Oxabact, and stable/increased levels with placebo, there was no significant difference between groups in the primary outcome (Least Squares mean estimate of treatment difference was - 3.80 μmol/L; 95% CI: - 7.83, 0.23; p-value = 0.064). Kidney function remained stable in both treatments. Oxabact treatment may have stabilized/reduced plasma oxalate versus a rise with placebo, but the difference over 12 months was not statistically significant (p = 0.06). A subtle effect observed with Oxabact suggests that O. formigenes may aid in preventing kidney stones. A higher resolution version of the Graphical abstract is available as Supplementary information.
Sections du résumé
BACKGROUND
Primary hyperoxalurias (PHs) are rare genetic diseases that increase the endogenous level of oxalate, a waste metabolite excreted predominantly by the kidneys and also the gut. Treatments aim to improve oxalate excretion, or reduce oxalate generation, to prevent kidney function deterioration. Oxalobacter formigenes is an oxalate metabolizing bacterium. This Phase III, double-blind, placebo-controlled randomized trial investigated the effectiveness of orally administered Oxabact™, a lyophilized O. formigenes formulation, at reducing plasma oxalate levels in patients suffering from PH.
METHODS
Subjects (≥ 2 years of age) with a diagnosis of PH and maintained but suboptimal kidney function (mean estimated glomerular filtration rate at baseline < 90 mL/min/1.73 m
RESULTS
Forty-three subjects were screened, 25 were recruited and one was discontinued. At Week 52, O. formigenes was established in the gut of subjects receiving Oxabact. Despite decreasing plasma oxalate level in subjects treated with Oxabact, and stable/increased levels with placebo, there was no significant difference between groups in the primary outcome (Least Squares mean estimate of treatment difference was - 3.80 μmol/L; 95% CI: - 7.83, 0.23; p-value = 0.064). Kidney function remained stable in both treatments.
CONCLUSIONS
Oxabact treatment may have stabilized/reduced plasma oxalate versus a rise with placebo, but the difference over 12 months was not statistically significant (p = 0.06). A subtle effect observed with Oxabact suggests that O. formigenes may aid in preventing kidney stones. A higher resolution version of the Graphical abstract is available as Supplementary information.
Identifiants
pubmed: 35552824
doi: 10.1007/s00467-022-05591-5
pii: 10.1007/s00467-022-05591-5
pmc: PMC9763141
doi:
Substances chimiques
Oxalates
0
Types de publication
Randomized Controlled Trial
Clinical Trial, Phase III
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
403-415Informations de copyright
© 2022. The Author(s).
Références
Pediatr Nephrol. 2021 Jul;36(7):1785-1793
pubmed: 33515281
Kidney Int. 2009 Jun;75(12):1264-1271
pubmed: 19225556
Urolithiasis. 2022 Apr;50(2):119-130
pubmed: 35122487
Am J Physiol Gastrointest Liver Physiol. 2011 Mar;300(3):G461-9
pubmed: 21163900
N Engl J Med. 2013 Aug 15;369(7):649-58
pubmed: 23944302
Pediatr Nephrol. 2017 May;32(5):781-790
pubmed: 27924398
Sci Rep. 2018 Sep 13;8(1):13731
pubmed: 30213974
J Clin Invest. 2013 Jan;123(1):236-46
pubmed: 23221343
Pediatr Nephrol. 2019 Feb;34(2):319-327
pubmed: 30276532
J Lab Clin Med. 2004 Jul;144(1):45-52
pubmed: 15252407
J Am Soc Nephrol. 2009 Mar;20(3):629-37
pubmed: 19158356
Urolithiasis. 2018 Aug;46(4):313-323
pubmed: 28718073
J Clin Endocrinol Metab. 2013 Mar;98(3):989-94
pubmed: 23348401
Nephrol Dial Transplant. 2011 Nov;26(11):3609-15
pubmed: 21460356
Kidney Int. 2006 Oct;70(7):1305-11
pubmed: 16850020
Int J Mol Sci. 2020 May 20;21(10):
pubmed: 32443777
Nephrol Dial Transplant. 2021 Jul 23;36(8):1464-1473
pubmed: 32810261
Circ J. 2010 Nov;74(11):2403-9
pubmed: 20921818
Urolithiasis. 2016 Aug;44(4):333-7
pubmed: 26857252
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Clin Biochem. 2017 Dec;50(18):1014-1019
pubmed: 28764885
Clin J Am Soc Nephrol. 2016 Jan 7;11(1):119-26
pubmed: 26656319
Kidney Int. 2006 Feb;69(4):691-8
pubmed: 16518326
N Engl J Med. 2021 Apr 1;384(13):1216-1226
pubmed: 33789010
J Am Soc Nephrol. 2011 Dec;22(12):2247-55
pubmed: 22021714
J Urol. 2011 Jul;186(1):135-9
pubmed: 21575973
Urolithiasis. 2013 Oct;41(5):379-84
pubmed: 23959075
Urol Res. 2010 Dec;38(6):429-38
pubmed: 20658131
Kidney Int. 2013 Nov;84(5):895-901
pubmed: 23739234